TICKERNERD
Menu
MTVAMTVAHealthcare · Biotechnology

MTVA Stock Forecast: MetaVia, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.47
+1.74% on the day

The 1 Wall Street analysts covering MetaVia, Inc. hold a median 12-month price target of $20 — +1265.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.6M
Ticker Nerd rank
17 / 100
Median analyst target
$20
Analysts covering
1
Total return, dividends reinvested
1W
−1.7%
1M
−7.3%
YTD
−82.6%
1Y
−79.2%
From 52W high
−91.1%
From 52W low
+51.0%
$1
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MTVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MetaVia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Growth
49
Accruals
47
Revisions
41
Momentum
26
Quality
20
Volatility
19
Issuance
15
Value
5

Size (93): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MTVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26MTVAHigh $30Median $20Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $8Median $20High $30

The green dot is the last close — the median target sits +1265.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 July 2026HC Wainwright & Co.ReiteratesBuy$20
18 May 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026HC Wainwright & Co.MaintainsBuy—
4 Sept 2025HC Wainwright & Co.AssumesBuy$12
19 May 2025Maxim GroupMaintainsBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MTVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MTVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

MetaVia, Inc. (MTVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−175.7%

Higher than 8% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MTVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MTVAMetaVia, Inc.$9.6M
17
FBLGFibroBiologics, Inc.$9.6M
47
AEONAEON Biopharma, Inc.$9.6M
48
OSRHOSR Health, Inc.$9.7M
24
LNAILunai Bioworks, Inc.$9.8M
31
SKYESkye Bioscience, Inc.$9.8M
34
IMNNImunon, Inc.$9.2M
22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MetaVia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MTVA news & analysis

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 6 Aug 2026positive

MetaVia Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. The company announced that all active patients in the ongoing Phase 1 Part 3 study of DA-1726 successfully reached the highest planned dose levels of 48 mg and 64 mg, with 16-week topline data expected in the fourth quarter of 2026.

Why it matters — A MetaVia watcher would care because this update signals clinical progress for DA-1726, with all active patients achieving target dose levels and key topline data anticipated in the fourth quarter of 2026.

FAQ

Frequently asked questions about MTVA stock

What is the MTVA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering MetaVia, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MTVA stock a buy right now?

Of the 1 analysts covering MetaVia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MetaVia, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MTVA?

As at 22 Aug 2026, MetaVia, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will MTVA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1265.2% from the last close, and Ticker Nerd's factor model ranks MetaVia, Inc. 17 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MTVA stock forecast for 2030?

No analyst covering MetaVia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.

How has MTVA stock performed over the past year?

MetaVia, Inc. returned -79.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MetaVia, Inc. do?

MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions.

What is the latest news on MTVA?

The most recent item we track (PRNewsWire, 6 Aug 2026): "MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update". MetaVia Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. The company announced that all active patients in the ongoing Phase 1 Part 3 study of DA-1726 successfully reached the highest planned dose levels of 48 mg and 64 mg, with 16-week topline data expected in the fourth quarter of 2026.

Company

About MetaVia, Inc.

MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions. The company concentrates on cardiometabolic diseases, including obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), as well as select central nervous system disorders. Its current pipeline includes DA-1726, being developed for obesity, and vanoglipel (DA-1241), a GPR119 agonist targeting MASH with potential relevance to Type 2 Diabetes Mellitus through modulation of gut hormones such as GLP-1, GIP, and peptide YY. MetaVia also develops ANA001, a proprietary oral niclosamide formulation, Gemcabene for acute indications including infectious and inflammatory settings, NB-01 for painful diabetic neuropathy, and NB-02 aimed at symptoms of cognitive impairment in neurodegenerative diseases. Operating within the biotechnology and health technology sectors, MetaVia plays a specialized role in addressing complex, high-burden diseases where there is significant medical need for new therapeutic options.

CEO Mr. Hyung Heon Kim · 8 employees · United States · https://www.metaviatx.com